Abstract 462P
Background
The aim of this study was to identify correlates of cognitive function among cancer survivors attending rehabilitation in a community setting.
Methods
Participants were 35 cancer patients who had reported memory issues and were screened by an occupational therapist for cognitive dysfunction. Using baseline data, descriptive and bivariate analyses were performed to detail the cognitive function of study sample and to identify its correlates.
Results
Study sample was predominantly female (94.7%) with breast cancer (65.8%) who had received chemotherapy (77.1%) and hormonal therapy (51.5%). Mean age was 53.8 ± 10.3 years and mean years since diagnosis was 4.9 ± 3.3 years. Mean scores of cognitive performances were within the norms for attention (digit span forward test; 7.5 ± 1.4), working memory (digit span backward test; 5.4 ± 1.3), processing speed (trail making test A; 25.1 ± 5.5), and executive function (trail making test B; 68.3 ± 33.6). Mean scores of perceived cognitive ability (15.5 ± 4.1) and cognitive-related quality of life (9.8 ± 3.7), measured by the FACT-Cog, were below the norms. Cancer survivors with more years since diagnosis performed better in executive function (r = .45). Poorer working memory (r = -.38) and lower cognitive-related quality of life (r = -.41) were also found to associate with increased fatigue intensity. Although sleep duration and distress rating were not related to cognitive function, shorter sleep duration (r = -.35) and higher distress rating (r = .37) correlated with higher fatigue intensity. All results were statistically significant at p < 0.05.
Conclusions
Cancer survivors may report reduced perceived cognitive ability and cognitive-related quality of life despite adequate performance on objective tests. This discrepancy could be due to the relationship of fatigue to working memory. Global evaluation of cognitive function considers cognitive performance during periods of more intense fatigue while objective tests provide information on cognitive performance when tested at a particular time and fatigue level. Managing fatigue including addressing distress and sleep issues may be potential strategies that can be employed to support cognitive function.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract